Antineoplasikoen albo-ondorioakzein dira eta nola maneiatzen dira?

  1. Lizardi Mutuberria, Aitziber 1
  2. Garcia de Andoin Barandiaran, Miren Josune 1
  3. Umerez Igartua, Maitane 1
  4. Ercilla Liceaga, Miren 1
  5. Landa Alberdi, June 1
  6. Leunda Eizmendi, Larraitz 1
  7. Urretavizcaya Anton, Mikel 1
  1. 1 Hospital Universitario de Donostia
    info

    Hospital Universitario de Donostia

    San Sebastián, España

    ROR https://ror.org/04fkwzm96

Journal:
Osagaiz: osasun-zientzien aldizkaria

ISSN: 2530-9412

Year of publication: 2021

Volume: 5

Issue: 2

Pages: 119-128

Type: Article

DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Osagaiz: osasun-zientzien aldizkaria

Abstract

The development of cancer treatment over the last two decades has been very important. Guided molecular therapy and inhibitors of immune control points have been developed and along with standard cytotoxic therapy, they have become common treatments for different types of cancer. The toxicity profile of these new therapies is different from that of cytotoxic therapy. Guided molecular therapy has a more sustainable toxicity profile, even if it causes undesirable effects of varying origin and severity. Inhibitors of immune control points, on the other hand, cause undesirable effects related to immunity. In order to provide adequate care to patients, it is necessary to know the most common adverse effects of these different antineoplastic groups, as well as to be trained in their management.

Data source: Dialnet